Prevention for LongevityInstitutionIntelligenceStandardWorkAboutDiscuss an opportunity

Decision Center

LiveDecision-support surface, not delegated decision authority.

What should P4L do next?

The engine converts live signals into decision priorities and explicit first actions.

OpportunityDecision priorityFirst 30 days
Prevention & Healthspan Adoption IntelligenceAct nowMaintain the broad adoption-intelligence system; map evidence, measures, technologies, payment, workflow, and safeguards; keep each monitored pathway source-dated and decision-bounded.
Medicare App Library Readiness NavigatorAct nowUse the current requirements decision object to map a product to one CMS use case, then document identity, network/FHIR connectivity, vetting, evidence, privacy, usability, equity, CMS review or an applicable ACCESS exemption, open questions, and the next source check.
Clinical Agentic AI Adoption & Control StandardAct nowDraft Agentic AI Adoption & Control Standard v0.1 and crosswalk it to ADVOCATE, HTI-5, FDA lifecycle monitoring and health-system governance.
PROSPR Healthspan Translation ObservatoryAct nowCreate a PROSPR project registry with endpoints, biomarkers, intervention, trial stage, regulatory objective and claim-readiness field.
AI-Ready Health Data & Interoperability Readiness MapAct nowReplace static USCDI references with version-aware standards objects and build a data-readiness crosswalk for AI/proactive-care use cases.
Real-Time Evidence Generation Readiness SprintWatchPilot one evidence-generation sprint against a representative DHT use case; document outputs as a reusable method.
CY 2027 RPM/RTM Business-Model Stress TestWatchBuild three reimbursement scenarios (proposal as written / partial / current-state continuation) and map operational exposure.
Authorized AI Device → Real Adoption TrackerWatchIngest FDA AI device list and add adoption evidence fields rather than duplicating FDA's authorization list.
IGoR / AI-Native Biomedical Research Translation WatchWatchTrack award/team selection and require demonstrated speed/reproducibility evidence before stronger claims.
Geroscience 2026 Agenda-to-Action BriefingWatchCreate the pre-summit issue map now and schedule a rapid post-event delta brief.

ACCESS source update

CMS’s accepted-applicant page was updated August 17, 2026 and lists more than 150 accepted organizations. CMS says private payers representing 165 million members across Medicare Advantage, Medicaid, and commercial coverage have committed to align with the ACCESS payment approach, with many beginning in 2026. Inclusion on the accepted-applicant list is not CMS endorsement and does not guarantee final participation; participation remains contingent on Medicare enrollment, an executed agreement, final approval, and other requirements.

CMS describes a ten-year model, rolling start dates, outcome-aligned payments, public reporting of aggregated risk-adjusted results, physician clinical oversight, clinical and data safeguards, and lifestyle/behavioral, diagnostic, medication, care-coordination, and technology-supported services.

CMS accepted applicants · CMS ACCESS model

Freshness / current-context queue

CLM-0002 · Current but high-volatility · source updated August 17, 2026

CMS’s accepted-applicant page was updated August 17, 2026 and lists more than 150 accepted organizations. CMS says private payers representing 165 million members across Medicare Advantage, Medicaid, and commercial coverage have committed to align with the ACCESS payment approach, with many beginning in 2026. Inclusion on the accepted-applicant list is not CMS endorsement and does not guarantee final participation; participation remains contingent on Medicare enrollment, an executed agreement, final approval, and other requirements.

Reason: The underlying participant list or proposed policy can change quickly.

Action: Reverify before publication or decision use.

CLM-0003 · Current but high-volatility

FDA's maintained TEMPO participant table currently lists four participants: SonderMind, Inc. / SonderMind Adjunctive Care Application (SACA); Limbic Inc. / Unpacked; Cadence Solutions, Inc. / HypertensionOS; and Dexcom, Inc. / Dexcom Glucose Health Program.

Reason: FDA’s maintained participant table is dynamic. It was reverified September 3, 2026 after FDA identified the page as updated August 21, 2026, and currently lists four participants. FDA states that effectiveness for the participating intended uses has not yet been evaluated.

Action: Use the current proof record and reverify the FDA maintained participant table before publication or consequential decision use.

CLM-0007 · Current 2026 SVAP-approved context; not the latest released version

ASTP/ONC approved USCDI v6 through the 2026 SVAP process.

Reason: USCDI v7 is the latest released version. USCDI v6 remains the 2026 SVAP Approved Version eligible for voluntary certified-health-IT updates beginning August 29, 2026.

Action: Route latest-release questions to CLM-0021; retain CLM-0007 for explicitly SVAP-specific questions and link the two records.

CLM-0016 · Proposed — comments due September 14, 2026

CMS's CY 2027 PFS proposal includes material proposed changes to RPM/RTM delivery and payment requirements. The public comment period closes September 14, 2026.

Reason: The underlying participant list or proposed policy can change quickly.

Action: If submitting public comment, meet the September 14, 2026 deadline; keep every provision labeled proposed until finalized.

CLM-0019 · Proposed rule · comment period closed 2026-02-27 · not final

ASTP/ONC's HTI-5 proposal explicitly discusses automated access to EHI and potentially autonomous AI systems.

Reason: HTI-5 remains proposed. It is not adopted law, a current certification requirement, permission to access EHI, or authorization for autonomous AI; final language may differ materially.

Action: Use only within the stated source, status, and evidence limits; reverify after a material source change or before consequential use.

This public intelligence capability distinguishes sourced facts from P4L interpretation and preserves evidence and provenance links. It is not medical advice.